Sprifermin

Sprifermin is another name for human recombinant FGF18. Its manufacturers hope it will soon enter clinical trials for treatment of knee osteoarthritis.[1]

References

  1. ↑ "Merck Announces Collaboration With Nordic Bioscience for Sprifermin in Osteoarthritis of the Knee". Merck Group. 18 March 2013. Retrieved 30 May 2013.
This article is issued from Wikipedia - version of the Friday, July 11, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.